GO:0018216 peptidyl-arginine methylation: Protein Modification, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0018216 peptidyl-arginine methylation is the biological process that adds a methyl group to an arginine residue in a protein.
• This modification is catalyzed by protein arginine methyltransferases (PRMTs) and is reversible through demethylation.
• Arginine methylation regulates histone function, and its crosstalk with citrullination (mediated by PAD enzymes) is critical in autoimmune and inflammatory diseases.
• Dysregulated peptidyl-arginine methylation is implicated in rheumatoid arthritis, cancer, and cardiac dysfunction.
• Key enzymes include PRMTs and peptidyl arginine deiminases (PADs), which antagonize methylation by converting arginine to citrulline.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential to dissect the causal roles of these enzymes in disease.
Description
Peptidyl-arginine methylation (GO:0018216) is a post-translational modification that transfers a methyl group to the guanidino nitrogen of an arginine residue in a protein. This process is fundamental to epigenetic regulation, signal transduction, and RNA metabolism, and it is catalyzed by a family of enzymes known as protein arginine methyltransferases (PRMTs). Because arginine methylation can alter protein-protein interactions, nucleic acid binding, and enzymatic activity, it serves as a key regulatory switch in diverse cellular pathways. The modification is dynamically controlled: while PRMTs add methyl groups, demethylases can remove them, and peptidyl arginine deiminases (PADs) can convert methylated arginine to citrulline, thereby antagonizing methylation. This interplay is especially relevant in autoimmunity, where altered methylation and citrullination of histones and other proteins contribute to disease pathogenesis. In cancer, histone citrullination and the resulting changes in methylation patterns have emerged as potential therapeutic targets. Moreover, inhibition of PAD4 has been shown to protect against myocardial infarction-induced cardiac dysfunction, highlighting the broad physiological importance of this modification. For researchers, understanding peptidyl-arginine methylation requires precise tools to manipulate the enzymes involved and to measure the modification at specific residues. This article provides a research-grade overview of GO:0018216, covering its definition, mechanism, key genes, disease links, and the CRISPR-based methods used to study it.
peptidyl-arginine methylation At A Glance
| GO ID | GO:0018216 |
|---|---|
| GO term | peptidyl-arginine methylation |
| Ontology | biological_process |
| Synonym | none |
| Definition | The addition of a methyl group to an arginine residue in a protein. |
| Major function | Post-translational modification regulating protein function, epigenetic marks, and signaling. |
| Key enzymes | Protein arginine methyltransferases (PRMTs); demethylases; peptidyl arginine deiminases (PADs) as antagonists. |
| Reversibility | Yes, via demethylases and conversion to citrulline by PADs. |
| Disease relevance | Rheumatoid arthritis, cancer, cardiac dysfunction, and other inflammatory conditions. |
What Is GO:0018216?
According to the Gene Ontology, peptidyl-arginine methylation (GO:0018216) is defined as the addition of a methyl group to an arginine residue in a protein. This covalent modification occurs on the side-chain nitrogen atoms of arginine and is carried out by protein arginine methyltransferases (PRMTs) using S-adenosylmethionine as the methyl donor. The reaction can produce monomethylarginine or dimethylarginine (symmetric or asymmetric), and it is reversible through the action of demethylases. The process is distinct from other types of protein methylation (e.g., lysine methylation) and is often studied in the context of histone modification and signal transduction.
Why Is peptidyl-arginine methylation Important in Cell Biology?
Peptidyl-arginine methylation is a central regulatory modification that impacts gene expression, RNA processing, DNA repair, and signal transduction. Its dynamic nature and crosstalk with other modifications, such as citrullination, make it a critical node in both normal physiology and disease. In autoimmune diseases like rheumatoid arthritis, altered methylation of histones and other proteins contributes to the breakdown of immune tolerance. In cancer, histone citrullination and the associated changes in methylation patterns can drive tumorigenesis and represent potential therapeutic targets. Furthermore, PAD4 inhibition protects against cardiac dysfunction after myocardial infarction, underscoring the clinical relevance of this pathway beyond autoimmunity. Understanding peptidyl-arginine methylation is therefore essential for developing targeted therapies and for interpreting epigenetic and proteomic data in biomedical research.
• Regulates chromatin structure and gene expression through histone arginine methylation.
• Modulates RNA-binding protein function and RNA metabolism.
• Antagonized by citrullination, linking methylation to autoimmune pathology.
• Implicated in rheumatoid arthritis via PAD4-mediated histone modification.
• Involved in cancer progression and as a target for anti-tumor strategies.
• Protective effects of PAD4 inhibition in myocardial infarction highlight cardiovascular relevance.
• Myelin basic protein charge isomers interact with PAD2, affecting myelin stability and neurodegeneration.
• Substrate preferences of PRMTs influence specificity and cellular outcomes.
• Provides a mechanism for dynamic regulation of protein function through reversible methylation.
• Offers opportunities for CRISPR-based functional studies and drug discovery.
What Happens During peptidyl-arginine methylation?
Substrate recognition and methyl transfer
In simple terms: Enzymes called PRMTs recognize specific arginine residues in target proteins and attach a methyl group to them.
Peptidyl-arginine methylation begins with the recognition of target arginine residues by protein arginine methyltransferases (PRMTs). These enzymes bind to substrate proteins, often in the context of specific sequence motifs, and catalyze the transfer of a methyl group from S-adenosylmethionine to the guanidino nitrogen of arginine. The reaction can produce monomethylarginine or dimethylarginine, with different PRMTs exhibiting distinct substrate preferences. This step is highly regulated and determines the specificity of the modification.
Formation of methylarginine derivatives
In simple terms: The initial methyl group can be further modified to create different types of methylarginine, which have distinct functional consequences.
Following the initial methylation, some PRMTs can add a second methyl group to the same arginine residue, generating asymmetric or symmetric dimethylarginine. These different methylation states are recognized by distinct reader proteins and can lead to different downstream effects. The type and extent of methylation are critical for the functional outcome, influencing protein interactions and activity.
Antagonism by citrullination
In simple terms: Another enzyme, PAD, can convert methylated arginine into citrulline, effectively removing the methylation mark and changing the protein's properties.
Peptidyl arginine deiminases (PADs) catalyze the conversion of arginine residues to citrulline, a process that antagonizes arginine methylation. This reaction is irreversible and can eliminate the methylation mark, thereby altering the protein's charge and function. In histones, citrullination by PAD4 has been shown to antagonize arginine methylation and impact chromatin structure. This crosstalk is particularly relevant in autoimmune diseases where PAD activity is dysregulated.
Demethylation and reversibility
In simple terms: Enzymes called demethylases can remove methyl groups from arginine, making the modification reversible and dynamic.
Arginine methylation is reversible through the action of demethylases, which remove methyl groups from methylarginine residues. This reversibility allows for dynamic regulation of protein function in response to cellular signals. The balance between methylation and demethylation is crucial for maintaining normal cellular physiology, and its disruption is associated with disease.
Functional consequences
In simple terms: The addition or removal of methyl groups changes how proteins interact with other molecules, affecting processes like gene expression and signaling.
Methylation of arginine residues can alter protein-protein interactions, nucleic acid binding, and enzymatic activity. In histones, arginine methylation serves as an epigenetic mark that influences transcription and chromatin remodeling. In non-histone proteins, it can modulate signaling pathways, RNA processing, and DNA repair. The functional outcome depends on the specific protein and the type of methylation.
Key Genes Involved in GO:0018216 peptidyl-arginine methylation
The following genes and proteins are central to peptidyl-arginine methylation and its regulation, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRMT1 | Protein arginine methyltransferase; catalyzes asymmetric dimethylation | Key enzyme in epigenetic regulation and cancer |
| PRMT5 | Protein arginine methyltransferase; catalyzes symmetric dimethylation | Involved in RNA processing and tumorigenesis |
| PRMT4 (CARM1) | Protein arginine methyltransferase; methylates histones and non-histone proteins | Regulates transcription and splicing |
| PADI4 (PAD4) | Peptidyl arginine deiminase; converts arginine to citrulline, antagonizing methylation | Implicated in rheumatoid arthritis and cancer |
| PADI2 (PAD2) | Peptidyl arginine deiminase; citrullinates myelin basic protein | Linked to neurodegeneration and myelin stability |
| Jmjd6 | Arginine demethylase; removes methyl groups from histones | Regulates gene expression and development |
| MBP | Myelin basic protein; target of citrullination by PAD2 | Charge isomers interact differently with PAD2, affecting myelin |
| Histone H3 | Substrate for arginine methylation and citrullination | Epigenetic mark crosstalk in disease |
| Histone H4 | Substrate for arginine methylation | Chromatin regulation |
| S-adenosylmethionine (SAM) | Methyl donor for PRMTs | Cofactor in methylation reactions |
| PRMT6 | Protein arginine methyltransferase | Regulates transcription and DNA repair |
| PRMT7 | Protein arginine methyltransferase | Involved in splicing and stress response |
| PRMT9 | Protein arginine methyltransferase | Methylates splicing factor SF3B2 |
| CARM1 | Coactivator-associated arginine methyltransferase 1 | Transcriptional coactivator |
| PAD4 | Peptidyl arginine deiminase 4 | Autoantigen in rheumatoid arthritis |
| PAD2 | Peptidyl arginine deiminase 2 | Myelin basic protein citrullination |
| SF3B2 | Splicing factor methylated by PRMT9 | RNA splicing regulation |
| Npl3 | RNA-binding protein methylated by PRMTs | mRNA export and processing |
How Is peptidyl-arginine methylation Regulated?
Peptidyl-arginine methylation is dynamically regulated by the opposing activities of PRMTs, demethylases, and PADs. The expression and activity of these enzymes are controlled at multiple levels, including transcriptional regulation, post-translational modifications, and interaction with regulatory proteins. For example, PRMT activity can be modulated by cellular signals that affect substrate availability or cofactor levels. Additionally, the crosstalk with citrullination provides a regulatory layer where PAD activity can eliminate methylation marks, thereby influencing downstream signaling. In disease states such as rheumatoid arthritis, altered expression of PAD4 and changes in histone methylation patterns have been observed, suggesting that dysregulation of this balance contributes to pathogenesis. Understanding these regulatory mechanisms is essential for developing targeted interventions.
peptidyl-arginine methylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PADI4 | Rheumatoid arthritis | Knockout mice or cell lines to study citrullination and autoimmunity |
| PADI2 | Neurodegeneration (myelin stability) | Point mutation or knockout in oligodendrocytes |
| PRMT1 | Cancer | Overexpression and knockout in tumor cell lines |
| PRMT5 | Cancer | Knockdown or inhibitor studies in cancer models |
| PAD4 | Cardiac dysfunction | Knockout mice subjected to myocardial infarction |
Rheumatoid Arthritis
Peptidyl-arginine methylation and its antagonism by citrullination are critically involved in rheumatoid arthritis (RA). PAD4, which converts arginine to citrulline, is a major autoantigen in RA, and its activity leads to the production of citrullinated proteins that trigger autoimmune responses. Studies have shown that PAD4 promoter hypomethylation is associated with RA, suggesting epigenetic dysregulation of the PADI4 gene. Furthermore, PAD4 influences histone methylation, contributing to the pathogenesis of RA. These findings highlight the importance of the methylation-citrullination axis in autoimmune disease.
Cancer
Histone citrullination, mediated by PADs, has emerged as a new target for tumors. The crosstalk between citrullination and arginine methylation affects chromatin structure and gene expression, influencing tumorigenesis. Dysregulated PRMT activity is also implicated in various cancers, where altered methylation patterns drive oncogenic pathways. Targeting these enzymes is a promising therapeutic strategy.
Cardiac Dysfunction
Inhibition of PAD4 protects against myocardial infarction-induced cardiac dysfunction. This suggests that peptidyl-arginine deiminase activity, which antagonizes methylation, plays a detrimental role in cardiac injury. The underlying mechanisms may involve altered protein function and inflammatory responses, but further research is needed to fully elucidate the pathways.
Neurodegeneration
Myelin basic protein (MBP) charge isomers interact differently with PAD2, affecting myelin stability. Citrullination of MBP by PAD2 is associated with demyelinating diseases, and the interplay with arginine methylation may contribute to neurodegeneration. Understanding these interactions could inform therapeutic approaches for multiple sclerosis and related disorders.
From peptidyl-arginine methylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PRMT1 drive tumor growth? | Knockout or knockdown in cancer cell lines and xenografts |
| How does PAD4 citrullination affect histone methylation? | Point mutation of PAD4 active site in cells |
| What is the role of PAD2 in myelin stability? | Knock-in of citrullination-resistant MBP in mice |
| Can PAD4 inhibition protect against cardiac dysfunction? | Knockout mice or pharmacological inhibitors in myocardial infarction models |
| How does PRMT5 substrate specificity affect splicing? | Overexpression of wild-type and mutant PRMT5 in cells |
| What are the epigenetic consequences of PADI4 hypomethylation? | CRISPR-mediated promoter methylation or knockout |
How to Study the peptidyl-arginine methylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot with methylarginine antibodies | Levels of methylated arginine in proteins | Detection of global changes in methylation |
| Mass spectrometry | Identification and quantification of methylation sites | Proteome-wide mapping of arginine methylation |
| CRISPR knockout screens | Genes required for methylation or disease phenotypes | Functional genomics of PRMTs and PADs |
| In vitro methyltransferase assay | Enzyme activity and substrate specificity | Characterization of PRMTs and inhibitor testing |
| Immunofluorescence | Subcellular localization of methylated proteins | Visualization of methylation in cells |
| Citrullination assay | Conversion of arginine to citrulline | Measurement of PAD activity |
| Co-immunoprecipitation | Protein-protein interactions of PRMTs/PADs | Identification of complexes |
| RNA-seq | Transcriptional changes upon perturbation | Downstream effects of methylation changes |
Antibody-based detection of methylarginine
Specific antibodies against mono- or dimethylarginine can be used in Western blot, immunoprecipitation, and immunofluorescence to detect and quantify peptidyl-arginine methylation in cells and tissues. These tools are essential for validating changes in methylation levels upon genetic or pharmacological perturbations.
Mass spectrometry-based proteomics
Mass spectrometry allows unbiased identification and quantification of arginine methylation sites on proteins. This approach can reveal global changes in methylation patterns and identify novel substrates of PRMTs. It is particularly useful for studying crosstalk with other modifications.
CRISPR-based genetic screens
CRISPR knockout screens can identify genes that regulate peptidyl-arginine methylation or that are required for the function of PRMTs and PADs. Such screens can uncover synthetic lethal interactions and potential drug targets.
Enzymatic activity assays
In vitro methyltransferase or deiminase assays using recombinant enzymes and peptide substrates can measure catalytic activity and substrate specificity. These assays are valuable for testing inhibitors and understanding enzyme kinetics.
How CRISPR Can Be Used to Study GO:0018216 peptidyl-arginine methylation
Knockout
CRISPR knockout of PRMTs or PADs can abolish their enzymatic activity, allowing researchers to study the loss-of-function phenotypes in cell models and animals. For example, PADI4 knockout mice have been used to investigate the role of citrullination in rheumatoid arthritis. Knockout of PRMT1 or PRMT5 can reveal essential functions in cell proliferation and survival.
Point Mutation
Introducing point mutations in the catalytic domain of PRMTs or PADs can dissect the importance of specific residues for substrate binding and catalysis. For instance, mutating the active-site cysteine of PAD4 can render it catalytically inactive, helping to distinguish enzymatic from scaffolding functions.
Knock-in
Knock-in of tagged or mutant versions of PRMTs and PADs allows for precise tracking and functional analysis. For example, knocking in a citrullination-resistant mutant of myelin basic protein can test the role of PAD2-mediated citrullination in myelin stability. Tagged knock-ins (e.g., FLAG or GFP) facilitate immunoprecipitation and imaging.
Overexpression
Overexpression of wild-type or mutant PRMTs/PADs can model gain-of-function states observed in cancer and autoimmune diseases. This approach is useful for identifying downstream targets and for testing inhibitors in a background of elevated enzyme activity.
How EDITGENE Supports peptidyl-arginine methylation Research
Researchers studying peptidyl-arginine methylation-related genes often need to determine whether a candidate gene is causally involved in a specific disease or cellular process. This requires precise genetic models that can knockout, mutate, knock-in, or overexpress the gene of interest. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such studies.
Contact EDITGENE today to design your custom CRISPR model for peptidyl-arginine methylation research.
Frequently Asked Questions About peptidyl-arginine methylation
What is peptidyl-arginine methylation?
Peptidyl-arginine methylation (GO:0018216) is the addition of a methyl group to an arginine residue in a protein, catalyzed by protein arginine methyltransferases (PRMTs).
What genes are involved in peptidyl-arginine methylation?
Key genes include PRMT1, PRMT5, CARM1 (PRMT4), and PADI4/PADI2, which encode enzymes that add or remove methyl groups or convert arginine to citrulline.
How is peptidyl-arginine methylation regulated?
It is regulated by the opposing activities of PRMTs, demethylases, and PADs, as well as by cellular signals and cofactor availability.
What diseases are associated with peptidyl-arginine methylation?
It is implicated in rheumatoid arthritis, cancer, cardiac dysfunction, and neurodegeneration.
What is the role of PAD4 in rheumatoid arthritis?
PAD4 citrullinates proteins, creating autoantigens, and its promoter hypomethylation is linked to RA pathogenesis.
How can CRISPR be used to study peptidyl-arginine methylation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of PRMTs and PADs in disease.
What methods detect arginine methylation?
Antibody-based detection, mass spectrometry, and enzymatic assays are commonly used.
Is arginine methylation reversible?
Yes, demethylases can remove methyl groups, and PADs can convert methylarginine to citrulline, antagonizing methylation.
What is the crosstalk between methylation and citrullination?
PAD enzymes convert arginine to citrulline, which eliminates methylation marks and alters protein function, impacting autoimmunity and cancer.
How does EDITGENE support research on peptidyl-arginine methylation?
EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to study these pathways.
Conclusion
Peptidyl-arginine methylation (GO:0018216) is a dynamic and reversible post-translational modification that regulates diverse cellular processes through the action of PRMTs, demethylases, and PADs. Its crosstalk with citrullination is particularly important in autoimmune diseases like rheumatoid arthritis, as well as in cancer and cardiac dysfunction. Understanding the molecular mechanisms and disease relevance of this modification requires sophisticated genetic models and analytical tools. CRISPR-based approaches, combined with proteomics and functional assays, are indispensable for dissecting the roles of individual enzymes and for identifying therapeutic targets. As research advances, targeting peptidyl-arginine methylation pathways holds promise for new treatments in autoimmunity, oncology, and cardiovascular disease.
References
- 1. Kolarz B et al.. 2020. Peptidyl Arginine Deiminase Type 4 Gene Promoter Hypo-Methylation in Rheumatoid Arthritis.. J Clin Med 9(7) PMID: 32629762
- 2. Wesche J et al.. 2017. Protein arginine methylation: a prominent modification and its demethylation.. Cell Mol Life Sci 74(18):3305-3315 PMID: 28364192
- 3. Cuthbert GL et al.. 2004. Histone deimination antagonizes arginine methylation.. Cell 118(5):545-53 PMID: 15339660
- 4. Zhu D et al.. 2021. Histone citrullination: a new target for tumors.. Mol Cancer 20(1):90 PMID: 34116679
- 5. Guo J et al.. 2013. [Peptidyl arginine deiminase 4 participates in the pathogenesis of rheumatoid arthritis by influencing histone methylation].. Zhonghua Nei Ke Za Zhi 52(11):928-31 PMID: 24439185
- 6. Du M et al.. 2020. Inhibition of peptidyl arginine deiminase-4 protects against myocardial infarction induced cardiac dysfunction.. Int Immunopharmacol 78:106055 PMID: 31816575
- 7. Mamulashvili N et al.. 2024. Myelin basic proteins charge isomers interact differently with the peptidyl arginine deiminase-2.. Neuroreport 35(3):185-190 PMID: 38305106
- 8. Thomas D et al.. 2014. Protein arginine N-methyltransferase substrate preferences for different nη-substituted arginyl peptides.. Chembiochem 15(11):1607-13 PMID: 25044481
